Vera Therapeutics VERA Debt-to-equity

Debt-to-equity at other companies

Vertex PharmaceuticalsVRTX

0.1×0.0×

Travere Therapeutics, Inc.TVTX

0.2×-2.6×

Aurinia PharmaceuticalsAUPH

0.1×-0.2×

Climb Bio, Inc.CLYM

0×0.0×

Jade BiosciencesJBIO

0×—

Viridian Therapeutics, Inc.VRDN

0.2×+0.1×

FAQ

What is Vera Therapeutics's debt-to-equity?

Vera Therapeutics (VERA) reported debt-to-equity of 0.2× in Q1 2026.

How has Vera Therapeutics's debt-to-equity changed year-over-year?

Vera Therapeutics's debt-to-equity increased by 47.4% year-over-year, from 0.1× to 0.2×.

What is the long-term trend for Vera Therapeutics's debt-to-equity?

Over 4 years (2021 to 2025), Vera Therapeutics's debt-to-equity has grown at a -9.8% compound annual growth rate (CAGR), from 0.2× to 0.1×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.